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An adequate vitamin D (vitD) intake (Recommended Daily Allowance, 
RDA= 5µg) is crucial for health maintenance and its deficiency is 
associated with several health problems. The increase in hypovitaminosis 
D cases and the proliferation of food supplements (FS) that are easily 
accessible by the population, have led to an unrestrained chronic 
consumption of FS. VitD may accumulate in the body and originate 
toxicity (Tolerable Upper Limit, UL=100 µg). The aim of this study was to 
evaluate if daily vitD doses mentioned in FS labels are in conformity with 
RDA. 210 solid and liquid FS (for pediatrics and adults) sold in Portuguese 
pharmacies, supermarkets, health shops and on the internet were examined 
for indicated daily intake of vitD and compared to RDA and UL values. 
51.43% of FS have values higher than RDA, 8.57% higher than UL. The 
average vitD daily dose in FS is 24.48 µg, with a high variability between 
samples (0.25 - 250 µg). Majority of FS labels recommend vitD daily doses 
above RDA and some even above UL, regardless of being for adults or 
children. Therefore, it is crucial that vitD dose in FS is reviewed to ensure 









Vitamin D (vitD) is a hormone crucial for the 
regulation of physiological processes, namely related to 
bone metabolism, immune system, cardiovascular and 
insulin synthesis, and has been associated with several 
pathologies [1-3]. It is a fat-soluble vitamin and is obtained 
endogenously, mainly from sun exposure where ultraviolet 
rays hit the skin and initiate vit D synthesis. It is also 
present in very few foods (yeast, fungi, cod liver oil and 
oily fish) and available in many food supplements (FS) as 
well as in fortified foods, such as dairy products. 
VitD has two isomers (vitD2 or ergocalciferol and 
vitD3 or cholecalciferol). VitD itself is biologically inert 
and must undergo two hydroxylations for activation: 
in the liver (producing calcidiol or 25-hydroxyvitamin 
D [25(OH)D = 25(OH)D2 and 25(OH)D3]) and in the 
kidney (forming calcitriol or 1α, 25-dihydroxyvitamin D 
[1α, 25(OH)2D2 and 1α, 25(OH)2D3) [4].
Homeostasis requires a daily plasma concentration 
of vitD. Human body levels are estimated mainly by the 
measurement of its major circulating form: 25(OH)D, 
which is considered an adequate indicator of the level of 
vitD in individuals [1]. Optimal vitD status is an important 
health issue and it is generally agreed that plasma or 
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serum levels of 25(OH)D should be used to assess vitD 
status, as they reflect both dietary intake and dermal 
production [5-7]. According to the U.S Institute of Medicine 
(IOM) and the UK National Osteoporosis Society (NOS) 
[4], 25(OH)D concentrations ≤30 nmol/L are considered 
deficient and concentrations between 30-50 nmol/L are 
insufficient. The scientific community consensually 
assumes that serum 25(OH)D concentrations below 25-
30 nmol/L should be prevented and treated. Additionally, 
values higher or equal to 50 nmol/L are included in 
several guidelines as an optimal concentration [7,8]. 
Regarding the consumption of vitamins and other 
nutrients, there are a number of terms that are used 
as such: the Recommended Dietary Allowance (RDA) 
which is the average daily intake, sufficient to meet the 
nutritional needs of the majority of the healthy population; 
Adequate Intake (AI), parameter that indicates the value 
corresponding to adequate nutritional intake, and is only 
used when there is insufficient scientific evidence to 
determine RDA, particularly in newborns and infants; 
and Tolerable Upper Intake Level (UL) that refers to the 
maximum recommended daily intake that does not cause 
adverse health effects and can be safely ingested without 
generating toxicity in the majority of the population [9,10]. 
In 2010, daily doses of 200 IU were considered by the 
Institute of Medicine, insufficient to maintain a desirable 
25(OH)D level. Hence, doses of 400 IU/ day (10 µg) for 
infants, 600 IU/ day (15 µg) for children, teenagers and 
adults, and 800 IU/ day (20 µg) for the elderly (over 70 
years) were suggested [19]. Although there are different 
recommendations for some subgroups of population, in 
most European countries, including Portugal, the RDA is 
set at 5 µg for all [11,12]. 
The dietary reference values (DRV) for vitD have been 
revised by the European Food Safety Authority (EFSA), 
based on an assessment carried out between 2013 and 
2016. The panel derived as Adequate Intakes (AI) for the 
EU population, assuming minimal sunshine exposure: 
infants aged 7-11 months: 10 µg/day and 15 µg/day for 
all groups aged one year and more (including pregnant/
lactating women). In the presence of cutaneous vitD 
synthesis, the values of intake should be lower or even 
zero [13].
EFSA also revised the UL for vitD, setting it at 100 
μg/day for adults, pregnant women and children over 11 
years old. UL values of 50 µg/day and 25 µg/day were 
proposed, respectively for 1-10 years old group and 
infants [14].
Considering the threshold values of 25(OH)D 
concentrations described above, there is a high worldwide 
prevalence of vitD deficiency, whose negative impact 
on public health requires public health measures such as 
fortification of foods with vitD [7].
VitD deficiency is common in Middle East countries, 
reaching up to 80% of the population. In European 
countries the values are lower with a prevalence of 
approximately 20% in Northern Europe and 30-60% in 
Western, Southern and Eastern Europe, but, more than 
10% of Europeans reveal a severe deficiency (serum 
25(OH)D <30 nmol/L) [7].
Several serious pathologies seem to be associated with 
VitD deficiency, such as multiple sclerosis, diabetes, heart 
disease, cancer, rickets [15-17]. 
Due to the growing awareness of vitD deficiency 
and associated health problems, it became a popular 
food supplement with a significant increase in the 
consumption of vitD-fortified food products, drugs and 
nutraceuticals. Given the high popularity of FS and the 
easy access to them by the general population without 
medical supervision, together with the growing number 
of prescriptions of vitD, including very high doses, there 
might be a greater risk of vitD intoxication, with or 
without hypervitaminosis [2,16]. 
Usually, overproduction of vitD following sun 
exposure, and ultimate toxicity is not likely to happen 
because it is a process regulated by a feedback loop, 
leading to photodegradation of the excess vitD produced 
[18,19]. On the other hand, exogenous forms of vitD may 
contribute to intoxication, when excessive amounts are 
consumed for a long time. The concern is greater for 
vitD3 than for vitD2 due to the higher bioavailability 
of the former [20,21]. Moreover, different formulations of 
vitD FS, originate significantly different plasma levels of 
25(OH)D [22].
Although vitD toxicity is considered to be rare, 
the consequences on health can be serious. The initial 
symptoms include confusion, weakness, fatigue, headache, 
appetite loss, nausea, vomiting, abdominal pain, polyuria, 
polydipsia, cardiovascular symptoms, among others [2,23]. 
Its clinical manifestations include severe hypercalcemia, 
hypercalciuria and hyperphosphatemia [2,19,24,25].
Although the toxicity of vitD is rarely appreciated, 
the medical community and health regulators are aware 
of the fact that it is one of the most toxic fat-soluble 
vitamins, hence the growing concern about increasing its 
consumption [7]. 
The policies and practices regarding voluntary 
fortification and legislation vary among European 
countries. The list of vitamin and minerals and their forms 
that can be added to FS is defined by The Commission 
Regulation (EC) No 1170/2009 of 30 November 2009 [25] 
. Commission Directive 2008/100/EC defines the labeling 
DOI: https://doi.org/10.30564/jim.v10i2.3716
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of foodstuffs with respect to the recommended daily 
allowance (RDA) [11]. This recommendation assumes that 
200 IU (5 g) vitD/day is sufficient to prevent rickets [26]. 
However, it ignores the physiological benefits of vitD. 
Currently, in Europe, most multivitamin preparations 
are labeled as “100% RDA” corresponding to 200 IU of 
cholecalciferol, 
FS are not meant for therapeutic purposes and should 
be used as a complement of a regular dietary intake of 
vitD and sunlight exposure, in order to achieve the RDA 
values. Hence, the goal of our work was to evaluate the 
information present on the label of vitD FS available 
on the Portuguese market, in terms of dosage and 
recommended daily allowance of vitD. 
2. Materials and Methods 
The daily intake of vitD described on 210 FS labels was 
analyzed and compared with the RDA. FS were available 
in Portuguese pharmacies, health shops, supermarkets and 
internet. Liquid and solid pharmaceutical forms whose 
label indicates the presence of vitD in their composition 
(in addition to other ingredients) were considered in the 
study, regardless of the use of the FS. 
For confidentiality issues, the commercial name 
of the products under study has been omitted and the 
designation FS has been adopted. Solid FS (SFS) included 
adult formulations, while liquid FS (LFS) included both 
pediatric and adult formulations.
A statistical analysis was carried out using Excel and 
SPSS Statistics (Statistical Package for Social Sciences) 
version 25.0 software for Windows.
3. Results
The 210 analyzed FS labels presented a vitD mean 
daily dose of 24.48 µg, with a high variability between 
samples (coefficient of variation =178.19%), with a 
minimum value of 0.25 and a maximum of 250 µg/day 
(Table 1). 
Table 1. VitD label daily dose values
Formulation N
VitD Label dose a  
(µg/day)
Mean ± SD b  
(µg/day)
Total FS 210 10.00 (0.25; 250.00) 24.48 ± 43.62
SFS 145 10.00 (1.20; 250.00) 24.56 ± 46.41
LFS 65 10.00 (0.25; 175.00) 24.31 ± 36.97
a VitD label dose, expressed as medians, with minimum and 
maximum values given in brackets; b SD-Standard Deviation
Analyzing the solid and liquid formulations separately, 
both presented similar values. To perform the comparison 
of vitD daily dose between the SFS and LFS, the non-
parametric test of Mann Whitney was applied, since vitD 
data have a non-normal distribution (p<0.05) in these 
groups. Following the application of the Mann Whitney 
test, no significant difference (p>0.05) was found between 
vitD daily dose in SFS and LFS.
Comparing recommended vitD daily doses indicated on 
the labels with the RDA established for vitD in Europe (5 
µg/day), it was found that the majority of FS, solids and 
liquids, have values far above RDA, including 12 SFS and 
6 LFS samples equal or higher than UL (Graph 1).
Graph 1. VitD label daily doses in solid and liquid FS
SFS with the highest vitD label value are those 
containing this vitamin as the sole ingredient. In 
multivitamin preparations, the daily dose of vitD reaches 
a maximum of 30 µg/day (FS_051). On the other hand, 
in LFS the highest levels were observed in multivitamins, 
with values that reach 175 µg/day (LFS_037). In LFS 
containing only vitD, the maximum value mentioned in 
the label is 125 µg/day (LFS_040).
Since LFS included pediatric (LFS_P; N=23) and 
adult (LFS_A; N=42) formulations, a comparison was 
also made between both sample groups using the Mann 
Whitney test. LFS_P presented a mean value of 25.05 ± 
30.67 µg/day (minimum= 0.25 µg/day, maximum=100 µg/
day); LFS_A presented a mean value of 23.90 ± 40.35 µg/
day (minimum= 0.5 µg/day, maximum=175 µg/day). The 
test result did not show any significant difference between 
these groups (p>0.05). The majority of LFS_P and LFS_
A labels mentioned values far above RDA, with two 
pediatric and four adult formulations equal or higher than 
UL, considering UL=100 μg/day in both groups (Graph 2). 
The number of LFS_P samples that exceeds UL rises to 
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Graph 2. VitD label doses in adult and pediatric LFS 
formulations
4. Discussion
In Europe, the established daily dose for vitD is 5 µg 
(RDA = 100%), which includes all sources of vitD (from 
diet to sun exposure and supplementation). However, 
there are FS that indicate values 50 times higher, which 
corresponds to 5000% of RDA and 250% of UL. 
Since vitD is fat-soluble, it tends to be distributed 
in the fat compartment such as adipose tissue resulting 
in a reduced clearance and accumulation in the body. 
Thus, regular intake of high doses should be monitored 
to prevent adverse effects such as kidney and heart 
disease and musculoskeletal pain. In addition, ingestion 
of excessive amounts of this vitamin can lead to elevated 
plasma and urine calcium levels, probably related to 
the excessive amount of 25(OH)D, not followed by its 
conversion to 1,25(OH)2D. In fact, plasma concentrations 
of 25(OH)D above 220 nmol/L can cause hypercalcemia 
leading to soft tissue calcification and ultimately damaging 
the heart and kidneys [27]. Babies are particularly sensitive 
to vitD overdoses due to high bone turnover. A study case 
was reported of a 4-month-old girl who received daily 
50,000 IU of vitD3 in liquid oral supplements, for two 
months, and suffered severe hypercalcemia, hypercalciuria 
and nephrocalcinosis [28]. Recently, a cross-sectional study 
on vitD toxicity was conducted in a pediatric toxicological 
referral center from Iran, on children younger than 12 
with a daily ingestion over 1500 IU of vitD [29]. The acute 
vitD toxicity in the pediatric population in Iran was found 
to be benign and probably related to the high prevalence 
of vitD deficiency in that country. A literature review 
on the risk of vitD toxicity in pediatrics concluded that 
although rare, cases of vitD intoxication causing dramatic 
life-threatening symptoms still occur in children [30].
Nevertheless, in our study, pediatric formulations had 
daily dose recommendations as high as those for adults, 
and in both cases, sometimes higher or equal than the UL 
of 100 µg/day.
5. Conclusions
FS are readily available and are poorly regulated. These 
conditions contribute to their overuse which, in the case of 
vitD, can trigger hypercalcemia. It is not understandable 
that FS labels suggest daily vitD doses higher that the 
RDA, especially considering that FS are not meant to treat 
hypovitaminosis and should serve only as a complement 
of a normal dietary regimen. To safeguard consumer 
safety, it is essential to have adequate and strict FS 
labelling legislation, in particular by ensuring compliance 
with the RDA values.
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